Bli medlem
Bli medlem

Du är här

2016-05-20

Zinzino: Interim Report 1st January - 31st March 2016, Zinzino AB (publ)

Strong growth in the Healthcare segment, which now represent over 80%
of sold goods increases profit in Q1.

FIRST QUARTER, Q1, 2016, (compared with the same period in the
previous year, 2015)

· Total income amounted to SEK 112.6 (111,2) million, which
represents a growth in sales of +1% (+44%).

· Gross profit amounted to SEK 41.1 (36.7) million and the gross
profit margin amounted to 36.5% (33.0%). The improvement in gross
profit was due to lower costs for goods sold and the increased share
of health products in the sales mix.

· EBITDA amounted to SEK 8.2 (8.9) million and the operating margin
before depreciation and amortisation amounted to 7.3% (8.0%).

· Pre-tax profit tax amounted to SEK 5.7 (6.5) m. Diluted earnings
per share before tax amounted to SEK 0.18 (0.22).

KEY EVENTS DURING THE PERIOD 1st JANUARY - 31st DECEMBER 2016

· Weak positive growth and good profitability thanks to further
margin improvements - due to continued efforts to streamline in-house
production, in combination with Zinzino Health having an increased
share in the quarter's sales mix, has led to gross margins further
improving.

· New IT system in full operation without any disruptions - the
project has been completed and during the first quarter the system
worked very well.

· Successful sales start in Germany during February - already in
March showing sales of SEK 0.8 million.

· Faun Pharma reports positive figures for the first quarter - the
company's external sales amounted to SEK 9.5 (9.2) million,
corresponding to a growth of 3% against the previous year and a net
profit of SEK 0.6 (-1.0) million, which was better than expected.
Furthermore, the ISO9001 certification is now officially ready.

· New establishment concept for the EU - during the first quarter
Zinzino has begun work on a new expansion model for the remaining
areas of the EU through its Swedish subsidiary Zinzino Sverige AB,
preliminary sales begin in the second quarter of 2016.

COMMENT BY CEO DAG BERGHEIM PETTERSEN:

Constant improvements, increased growth and health are central to our
strategy

The first quarter
During the first quarter we continued to work hard to enable our
ambitious goals and long-term strategies. We will increase the number
of customers by ten times the current level, and in the year 2020 we
will have one million customers. To achieve that requires preparation
and hard work. But also a clear strategy and I feel confident that we
are continuing to follow that. I am confident that we will achieve
our goal thanks to the amazing products that we develop and produce
in our own factory, our strong marketing with a focus on controlled
expansion and a level of commitment in our organisation that is
absolutely spectacular.

Constant improvements
In the main, I am very pleased with our progress during the first
quarter. We are increasing the number of customers and our product
range is constantly evolving and we have many strong new products on
the way. Our organisation has shown considerable commitment to our
continuous improvements, and our partners who sell our products have
been impressive. We can after the first quarter of 2016 show that we
again have a positive growth of one per cent against the previous
year and it is completely according to plan. Our success in doing
this is partly due to our transition to more profitable and
attractive health products, giving us better margins and good
internal costs control. I am proud that we successfully made major
investments in our own organisation, marketing, development of new
concepts and at the same time have been able to place a strong focus
on new markets, of which our launch in Germany during the quarter is
an example, and that our first quarter of 2016 has again seen
positive growth. It bodes well for the future.

Health
Four years ago we were a coffee company that started to poke its nose
into health. Today, our health sales account for 80 percent of
turnover and 90 percent of our profitability. We have in the years
since, acquired an ISO certified factory, where we develop and
produce our Balance products. This gives us full control of our
products and we can offer the best possible quality. It has also made
it possible for us to always be incredibly proud of our Balance
products and we have quickly gained a large customer base who really
appreciate them. The big change that we implemented then to focus on
health with our own Balance products has now really taken hold and
it's time for the next step. Our new concept will be launched on 1st
July, and in our segment it will make a substantial impression on the
entire health industry for a long time to come, in the same way that
Apple made their mark with the iPhone in the mobile phone industry.

Inspire Change

Dag Bergheim Pettersen, CEO, Zinzino AB

For a full report, please see the attached PDF.

This information comprises information that Zinzino AB must disclose
under the Securities Market Act and/or the Financial Instruments
Trading Act. The information was released for publication on 20th May
2016.

Certified Adviser for Zinzino AB is Erik Penser Bankaktiebolag

INFORMATION ABOUT THE COMPANY Zinzino was founded under the name
Zinzino Holding in autumn 2007. In 2009, the company acquired 93% of
the equity and 97% of the votes in Zinzino Nordic AB, partly by means
of a non-cash issue and partly by means of a private placement.
Zinzino Nordic is a sales company that uses independent distributors
to market and sell products for commission via so-called direct
sales.

NEXT REPORT
Interim report Q2 2016, published on 31/08/2016.

For further information:
Dag Bergheim Pettersen, CEO, Zinzino, Tel. +47 (0) 93 22 57 00
Fredrik Nielsen, CFO, Zinzino, Tel. +46 (0) 707 900 174

Photos for publication free of charge:
Anders Ekhammar, Tel. +46 (0) 707 462 579, www.zinzino.se

Zinzino AB is a leading direct sales company with a presence in
Sweden, Norway, Denmark, Finland, Iceland, Estonia, Latvia, Lithuania
the Faroe Islands, Poland, the Netherlands, Canada and the USA.
Zinzino markets and sells products within two product lines; Zinzino
Health, with a focus on long-term health, and Zinzino Coffee,
consisting of espresso machines, coffee, tea and accessories. Zinzino
offers customers products with a focus on quality, the environment,
health and a feeling of everyday luxury. Our values are characterised
by our high quality, proximity to customers and focus on active
product development. The products are marketed via direct sales.
Zinzino owns the Norwegian knowledge company BioActive Foods AS, and
the research and production unit Faun Pharma AS. Since 2005 Zinzino
has been a general agent for the Franco-Belgian coffee house Rombouts
& Malongo. Today Zinzino has around 90 employees in the Group.
Zinzino is headquartered in Gothenburg, with a factory in Oslo and
offices in Oslo, Florida and Helsinki.

-----------------------------------------------------------
http://news.cision.com/zinzino/r/interim-report-1st-january---31st-march...
http://mb.cision.com/Main/10976/2013858/518704.pdf
http://mb.cision.com/Public/10976/2013858/96eee0480e7ad22c.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.